afabicin   Click here for help

GtoPdb Ligand ID: 10754

Synonyms: AFN-1720 | Debio 1450 | Debio1450
Compound class: Synthetic organic
Comment: Afabicin (DEBIO 1450) is an inhibitor of bacterial Fabl, the NADH-dependent enoyl reductase from the type II bacterial fatty acid biosynthesis pathway (FAS-II) [3]. This is a prodrug whose active metabolite is DEBIO 1452 (previously AFN-1252; PubChem CID: 10407120) [1].
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 9
Hydrogen bond donors 2
Rotatable bonds 8
Topological polar surface area 143.22
Molecular weight 485.14
XLogP 0.53
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES O=C(N(Cc1oc2c(c1C)cccc2)C)/C=C/c1cnc2c(c1)CCC(=O)N2COP(=O)(O)O
Isomeric SMILES O=C(N(Cc1oc2c(c1C)cccc2)C)/C=C/c1cnc2c(c1)CCC(=O)N2COP(=O)(O)O
InChI InChI=1S/C23H24N3O7P/c1-15-18-5-3-4-6-19(18)33-20(15)13-25(2)21(27)9-7-16-11-17-8-10-22(28)26(23(17)24-12-16)14-32-34(29,30)31/h3-7,9,11-12H,8,10,13-14H2,1-2H3,(H2,29,30,31)/b9-7+
InChI Key HFYMDQMXVPJNTH-VQHVLOKHSA-N
No information available.
Summary of Clinical Use Click here for help
Afabicin has progressed to Phase 2 clinical evaluation for Staphylococcal bone or joint infections, or skin infections.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03723551 Study to Assess Safety, Tolerability and Efficacy of Afabicin in The Treatment of Participants With Bone or Joint Infection Due to Staphylococcus Phase 2 Interventional Debiopharm International SA
NCT02726438 Drug Penetration Into Bone After Repeated Oral Administration of Debio 1450 to Patients Undergoing Hip Replacement Surgery Phase 1 Interventional Debiopharm International SA This study confirmed drug penetration Into bone after repeated oral administration. 2
NCT02426918 Study of Debio 1450 for Bacterial Skin Infections Phase 2 Interventional Debiopharm International SA 4